EUVIMEDEUVIMED entdecken
Crossref

Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model

Bai-Ling Zhang, Hui Li, Wei-Xiao Wang, Xiu-Zhen Chen, Le-Le Xiong, Chen-Hu Ma, Ying Chen, Peng-Cheng Yi, Ming-Yu Jiang, Yi Xu, Jing-Han Gao, Du-Xian Liu und 2 weitere

Journal of Antimicrobial Chemotherapy · 03.06.2025 · 80 (6) · 1613-1625

DOI: 10.1093/jac/dkaf110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 09.04.2025. Verfasst von Bai-Ling Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Bacteremia, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Provincial Health Commission Bureau Foundation of Jiangxi, Provincial Administration of Traditional Chinese Medicine science and technology plan key project of Jiangxi, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Acinetobacter baumannii bacteremia caused by pandrug-resistant strains poses a major challenge in intensive care units, necessitating novel therapeutic approaches. Phage-derived depolymerases offer a promising adjunct to conventional antibiotics. However, studies on A. baumannii phage depolymerases have been limited to non-mammalian models. This study investigates the therapeutic efficacy, safety, and potential mechanisms of action of DPO-HL, both as a monotherapy and in combination with polymyxin B, in a murine model of A. baumannii bacteremia.

Methods

DPO-HL was expressed and purified via Ni-NTA affinity chromatography. Its bactericidal activity was assessed through dynamic killing and biofilm disruption assays. Interaction with human plasma was examined to determine its impact on plasma’s bactericidal activity. Synergy with polymyxin B was evaluated by MIC reduction. Safety was assessed via cytotoxicity, haemolysis, and acute toxicity tests. A mouse bacteremia model was established to evaluate therapeutic efficacy via intraperitoneal and intravenous administration.

Results

DPO-HL, targeting KL160 capsular polysaccharide, exhibited stability in plasma and enhanced plasma’s bactericidal effect. It showed strong synergy with polymyxin B, reducing its MIC by 16-fold, and efficiently eradicated mature biofilms. DPO-HL alone reduced bacterial load and endotoxin levels but rescued only 30% of bacteremia mice. Combination therapy (1.45 mg/kg DPO-HL + 0.5 mg/kg polymyxin B) significantly reduced endotoxin levels and achieved 100% survival, regardless of administration route.

Conclusions

This study identifies a KL160-targeting depolymerase and demonstrates its potent synergy with polymyxin B in treating A. baumannii bacteremia, supporting its potential for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAcinetobacter InfectionsBacteremiaAnti-Bacterial AgentsPolymyxin BAnimalsDisease Models, AnimalMiceBiofilmsMicrobial Sensitivity TestsHumansDrug SynergismFemaleDrug Resistance, Multiple, BacterialTreatment OutcomeDrug Therapy, Combination

Substanzen

Anti-Bacterial AgentsPolymyxin B

Autor:innen und Institutionen

  • Department of Blood Transfusion, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Department of Tuberculosis, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210003, China.
  • Clinical Research Center, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210003, China.
  • Department of Geriatric Medicine, Jiangxi Provincial People's Hospital, No. 92, Aiguo Road, Donghu District, Nanchang 330006, China.
  • Department of Pathology, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210003, China.
  • Department of Clinical Laboratory, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210003, China.

ORCID-Profile: Wei Chen

Förderung

  • Provincial Health Commission Bureau Foundation of Jiangxi
  • Provincial Administration of Traditional Chinese Medicine science and technology plan key project of Jiangxi
  • National Natural Science Foundation of China
  • General Project of Nanjing Municipal Health Commission Bureau
  • Talent Lift Foundation of the Second Hospital of Nanjing

Zitieren

APA

Zhang, B. L., Li, H., Wang, W. X., Chen, X. Z., Xiong, L. L., Ma, C. H., Chen, Y., Yi, P. C., Jiang, M. Y., Xu, Y., Gao, J. H., Liu, D. X., Yu, J. H., & Chen, W. (2025). Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model. Journal of Antimicrobial Chemotherapy, 80(6), 1613-1625. https://doi.org/10.1093/jac/dkaf110

Vancouver

Zhang BL, Li H, Wang WX, Chen XZ, Xiong LL, Ma CH, et al. Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model. Journal of Antimicrobial Chemotherapy. 2025;80(6):1613-1625. doi:10.1093/jac/dkaf110

BibTeX
@article{Zhang2025,
  author = {Zhang, Bai-Ling and Li, Hui and Wang, Wei-Xiao and Chen, Xiu-Zhen and Xiong, Le-Le and Ma, Chen-Hu and Chen, Ying and Yi, Peng-Cheng and Jiang, Ming-Yu and Xu, Yi and Gao, Jing-Han and Liu, Du-Xian and Yu, Jin-Hong and Chen, Wei},
  title = {Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {6},
  pages = {1613--1625},
  doi = {10.1093/jac/dkaf110}
}
Kostenlos starten →